Share 'GSK Update'
Update from GSK on the progress of their drisapersen (previously GSK2402968) clinical development program: To keep you current on the progress of the drisapersen (previously GSK2402968) clinical development program, as you have requested, I am writing to inform you that the last patient has been recruited within the drisapersen US Phase II clinical study [www.clinicaltrials.gov NCT01462292]. Thi…
You can share this blog post in two ways…
© 2022 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
